Your browser doesn't support javascript.
loading
Impact of the coronavirus disease 2019 (COVID-19) pandemic on pediatric oncology care in the Middle East, North Africa, and West Asia region: A report from the Pediatric Oncology East and Mediterranean (POEM) group.
Saab, Raya; Obeid, Anas; Gachi, Fatiha; Boudiaf, Houda; Sargsyan, Lilit; Al-Saad, Khulood; Javakhadze, Tamar; Mehrvar, Azim; Abbas, Sawsan Sati; Abed Al-Agele, Yasir Saadoon; Al-Haddad, Salma; Al Ani, Mouroge Hashim; Al-Sweedan, Suleiman; Al Kofide, Amani; Jastaniah, Wasil; Khalifa, Nisreen; Bechara, Elie; Baassiri, Malek; Noun, Peter; El-Houdzi, Jamila; Khattab, Mohammed; Sagar Sharma, Krishna; Wali, Yasser; Mushtaq, Naureen; Batool, Aliya; Faizan, Mahwish; Raza, Muhammad Rafie; Najajreh, Mohammad; Mohammed Abdallah, Mohammed Awad; Sousan, Ghada; Ghanem, Khaled M; Kocak, Ulker; Kutluk, Tezer; Demir, Haci Ahmet; Hodeish, Hamoud; Muwakkit, Samar; Belgaumi, Asim; Al-Rawas, Abdul-Hakim; Jeha, Sima.
Afiliação
  • Saab R; Children's Cancer Institute, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Obeid A; Children's Cancer Institute, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Gachi F; Department of Pediatrics, Pierre and Marie Curie Center, Algiers, Algeria.
  • Boudiaf H; Department of Pediatrics, Mustapha Pacha Hospital, Moustapha, Algeria.
  • Sargsyan L; Pediatric Cancer and Blood Disorders Center of Armenia, Professor R.H. Yeolyan Hematology Center, Yerevan, Armenia.
  • Al-Saad K; Department of Pediatrics, Salmaniya Medical Complex, Manama, Bahrain.
  • Javakhadze T; Department of Pediatrics, Iashvili Children's Central Hospital, Tbilisi, Georgia.
  • Mehrvar A; MAHAK Pediatric Cancer Treatment and Research Center, Tehran, Iran.
  • Abbas SS; Department of Pediatrics, Al-Imamian Al-Kadhimiyain Medical City, Baghdad, Iraq.
  • Abed Al-Agele YS; Department of Pediatrics, Ibn al-Athir Teaching Hospital for Children, Al-Mausil, Iraq.
  • Al-Haddad S; Department of Pediatrics, Children Welfare Teaching Hospital, Medical City, Baghdad, Iraq.
  • Al Ani MH; Department of Pediatrics, Nanakaly Hospital for Blood Disease, Kurdistan, Iraq.
  • Al-Sweedan S; Department of Pediatrics, King Abdullah University Hospital, Ar Ramtha, Jordan.
  • Al Kofide A; Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.
  • Jastaniah W; Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah, Kingdom of Saudi Arabia.
  • Khalifa N; College of Medicine, Umm AlQura University, Makkah, Kingdom of Saudi Arabia.
  • Bechara E; National Bank of Kuwait Children's Hospital, Kuwait City, Kuwait.
  • Baassiri M; Department of Pediatrics, Lebanese Hospital Geitaoui, Beirut, Lebanon.
  • Noun P; Department of Pediatrics, Makassed General Hospital, Beirut, Lebanon.
  • El-Houdzi J; Department of Pediatrics, Hammoud Hospital University Medical Center, Saida, Lebanon.
  • Khattab M; Department of Pediatrics, St George Hospital University Medical Center, Beirut, Lebanon.
  • Sagar Sharma K; Department of Pediatric Hematology-Oncology, Mohammed VI Marrakech University Hospital Center, Marrakech, Morocco.
  • Wali Y; Pediatric Hematology and Oncology Center, Ibn Sina University Hospital Center, Rabat, Morocco.
  • Mushtaq N; Department of Medical Oncology, B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal.
  • Batool A; Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman.
  • Faizan M; Department of Pediatrics, Aga Khan University Hospital, Karachi, Pakistan.
  • Raza MR; Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Dr. Akbar Niazi Teaching Hospital, Islamabad, Pakistan.
  • Najajreh M; Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, The Children's Hospital and the Institute of Child Health, Lahore, Pakistan.
  • Mohammed Abdallah MA; Department of Pediatric Oncology, The Indus Hospital, Karachi, Pakistan.
  • Sousan G; Huda Al Masri Pediatric Cancer Department, Beit Jala Governmental Hospital, Beit Jala, Palestine.
  • Ghanem KM; Department of Pediatrics, Khartoum Oncology Hospital, Khartoum, Sudan.
  • Kocak U; Department of Pediatrics, Al Bairouni Hospital, Damascus, Syria.
  • Kutluk T; Basma Pediatric Oncology Unit, Al Bairouni Hospital, Damascus, Syria.
  • Demir HA; Department of Pediatrics, Gazi University Hospital, Ankara, Turkey.
  • Hodeish H; Department of Pediatric Oncology, Hacettepe University Cancer Institute and Faculty of Medicine, Ankara, Turkey.
  • Muwakkit S; Department of Pediatric Hematology-Oncology, Private Memorial Ankara Hospital, Ankara, Turkey.
  • Belgaumi A; Pediatric Oncology Department, National Oncology Center, Sana'a, Yemen.
  • Al-Rawas AH; Children's Cancer Institute, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Jeha S; Department of Pediatrics, Aga Khan University Hospital, Karachi, Pakistan.
Cancer ; 126(18): 4235-4245, 2020 09 15.
Article em En | MEDLINE | ID: mdl-32648950
ABSTRACT

BACKGROUND:

Childhood cancer is a highly curable disease when timely diagnosis and appropriate therapy are provided. A negative impact of the coronavirus disease 2019 (COVID-19) pandemic on access to care for children with cancer is likely but has not been evaluated.

METHODS:

A 34-item survey focusing on barriers to pediatric oncology management during the COVID-19 pandemic was distributed to heads of pediatric oncology units within the Pediatric Oncology East and Mediterranean (POEM) collaborative group, from the Middle East, North Africa, and West Asia. Responses were collected on April 11 through 22, 2020. Corresponding rates of proven COVID-19 cases and deaths were retrieved from the World Health Organization database.

RESULTS:

In total, 34 centers from 19 countries participated. Almost all centers applied guidelines to optimize resource utilization and safety, including delaying off-treatment visits, rotating and reducing staff, and implementing social distancing, hand hygiene measures, and personal protective equipment use. Essential treatments, including chemotherapy, surgery, and radiation therapy, were delayed in 29% to 44% of centers, and 24% of centers restricted acceptance of new patients. Clinical care delivery was reported as negatively affected in 28% of centers. Greater than 70% of centers reported shortages in blood products, and 47% to 62% reported interruptions in surgery and radiation as well as medication shortages. However, bed availability was affected in <30% of centers, reflecting the low rates of COVID-19 hospitalizations in the corresponding countries at the time of the survey.

CONCLUSIONS:

Mechanisms to approach childhood cancer treatment delivery during crises need to be re-evaluated, because treatment interruptions and delays are expected to affect patient outcomes in this otherwise largely curable disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limite: Child / Humans País/Região como assunto: Africa / Asia Idioma: En Revista: Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Líbano

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limite: Child / Humans País/Região como assunto: Africa / Asia Idioma: En Revista: Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Líbano